Opioids and controlled-substance pain medications
Long-acting opioids, IR opioids, ER formulations. Federal CDC guidelines and state laws have tightened access — denials commonly involve daily MME limits and forced tapers.
What this class is
Controlled-substance pain medications include opioids (morphine, oxycodone, hydrocodone, fentanyl, methadone, etc.) and certain non-opioid controlled substances (gabapentinoids in some states). Federal CDC Opioid Prescribing Guidelines (2022 update) and state-specific laws have tightened daily MME thresholds. Patients on chronic stable opioid therapy commonly face plan-driven involuntary tapers — most are appealable when the patient is stable, functional, and not exhibiting OUD.
Representative drugs
- Long-acting opioids (MS Contin, OxyContin, fentanyl patches, methadone)
- Immediate-release opioids (oxycodone, hydrocodone)
- Buprenorphine for pain (Belbuca, Butrans)
- Tapentadol (Nucynta)
- Tramadol
Common denial patterns
- Plan-driven involuntary taper for stable chronic-pain patient
- Daily MME limit exceeded
- Quantity limits below FDA-labeled dosing
- Step therapy requiring non-opioid trial first (even when prior non-opioid failed)
Clinical guidelines that win appeals
- CDC Opioid Prescribing Guideline 2022 update
- VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain
Frequently asked questions
What is opioids and controlled-substance pain medications?
Controlled-substance pain medications include opioids (morphine, oxycodone, hydrocodone, fentanyl, methadone, etc.) and certain non-opioid controlled substances (gabapentinoids in some states). Federal CDC Opioid Prescribing Guidelines (2022 update) and state-specific laws have tightened daily MME thresholds. Patients on chronic stable opioid therapy commonly face plan-driven involuntary tapers — most are appealable when the patient is stable, functional, and not exhibiting OUD.
What are the common denial patterns?
Plan-driven involuntary taper for stable chronic-pain patient; Daily MME limit exceeded; Quantity limits below FDA-labeled dosing; Step therapy requiring non-opioid trial first (even when prior non-opioid failed).
Which clinical guidelines support appeals?
CDC Opioid Prescribing Guideline 2022 update; VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain.
Related
- Interventional pain — SCS, RFA, ESI, kyphoplastySpinal cord stimulators, intrathecal pumps, RFA, ESI, SI fusion
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
Sources
Appeal a opioids and controlled-substance pain medications denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com